Reid Weyant Merryman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 13 | 2023 | 1415 | 3.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5442 | 2.260 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2023 | 233 | 1.520 |
Why?
|
| Transplantation, Autologous | 12 | 2023 | 2124 | 1.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 1378 | 1.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2020 | 1381 | 0.910 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 9239 | 0.810 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2023 | 1270 | 0.760 |
Why?
|
| Lymphoma, Follicular | 1 | 2023 | 435 | 0.700 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.690 |
Why?
|
| Salvage Therapy | 4 | 2021 | 1275 | 0.640 |
Why?
|
| Immune Evasion | 1 | 2019 | 360 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11524 | 0.460 |
Why?
|
| Stem Cell Transplantation | 5 | 2023 | 1620 | 0.440 |
Why?
|
| Asparaginase | 1 | 2012 | 236 | 0.380 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 973 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5172 | 0.340 |
Why?
|
| Lymphoma | 1 | 2017 | 1877 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13695 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 1836 | 0.270 |
Why?
|
| Transplantation Conditioning | 4 | 2021 | 1598 | 0.260 |
Why?
|
| Schools, Medical | 1 | 2011 | 880 | 0.240 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 4776 | 0.230 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 6234 | 0.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 1519 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 9274 | 0.220 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2023 | 134 | 0.200 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 380 | 0.190 |
Why?
|
| Disease-Free Survival | 6 | 2023 | 6895 | 0.180 |
Why?
|
| Education, Medical | 1 | 2011 | 1721 | 0.170 |
Why?
|
| Humans | 30 | 2023 | 744343 | 0.170 |
Why?
|
| Health Policy | 1 | 2011 | 2661 | 0.160 |
Why?
|
| Retrospective Studies | 11 | 2022 | 77449 | 0.160 |
Why?
|
| Cytarabine | 1 | 2020 | 692 | 0.160 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 164 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8642 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 193 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2023 | 1357 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2022 | 901 | 0.120 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 2957 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.120 |
Why?
|
| Survival Rate | 4 | 2022 | 12788 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7913 | 0.120 |
Why?
|
| Prognosis | 3 | 2022 | 29063 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3586 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 987 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2886 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2023 | 4445 | 0.090 |
Why?
|
| Adult | 10 | 2023 | 214055 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1434 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 10180 | 0.080 |
Why?
|
| Young Adult | 3 | 2021 | 56430 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 21683 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2023 | 63114 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
| Methotrexate | 1 | 2012 | 1727 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1832 | 0.060 |
Why?
|
| Aged | 8 | 2022 | 163280 | 0.060 |
Why?
|
| Female | 9 | 2022 | 380194 | 0.060 |
Why?
|
| Middle Aged | 7 | 2022 | 213383 | 0.050 |
Why?
|
| Data Collection | 1 | 2011 | 3341 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 85781 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39050 | 0.040 |
Why?
|
| Recurrence | 2 | 2022 | 8340 | 0.040 |
Why?
|
| Male | 7 | 2022 | 350118 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 40561 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 2016 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 2386 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 35136 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 41006 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53288 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 57776 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 10252 | 0.010 |
Why?
|
| Gene Expression | 1 | 2017 | 7799 | 0.010 |
Why?
|
| Child | 1 | 2012 | 77709 | 0.010 |
Why?
|
| United States | 1 | 2011 | 69872 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12804 | 0.010 |
Why?
|